Cargando…
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
Results from cardiovascular outcome trials (CVOT) with 5 different sodium-glucose co-transporter 2 inhibitors (SGLT2i; empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin), initially developed for their glucose-lowering effect by blocking tubular glucose reabsorption in kidney,...
Autores principales: | Oh, Jaewon, Lee, Seung-Hyun, Lee, Chan Joo, Kang, Seok-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112180/ https://www.ncbi.nlm.nih.gov/pubmed/33975387 http://dx.doi.org/10.4070/kcj.2021.0070 |
Ejemplares similares
-
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
por: Packer, Milton, et al.
Publicado: (2023) -
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
por: Lopaschuk, Gary D., et al.
Publicado: (2020) -
Regulatory RNAs in Heart Failure
por: Gomes, Clarissa Pedrosa da Costa, et al.
Publicado: (2020) -
Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
por: Kubota, Yoshiaki, et al.
Publicado: (2022) -
Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis
por: Liu, Yi, et al.
Publicado: (2023)